Price T Rowe Associates Inc Arvinas, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,103,011 shares of ARVN stock, worth $70.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,103,011
Previous 3,853,716
6.47%
Holding current value
$70.8 Million
Previous $94.9 Million
17.13%
% of portfolio
0.01%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding ARVN
# of Institutions
224Shares Held
70.9MCall Options Held
1.52MPut Options Held
346K-
Vanguard Group Inc Valley Forge, PA7.06MShares$122 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$116 Million6.03% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$108 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$57.6 Million1.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.07MShares$53 Million0.01% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $918M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...